Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance
Frontiers in Oncology · 20.07.2026 · 16
DOI: 10.3389/fonc.2026.1911991 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 20.07.2026. Verfasst von Shihang Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Hebei North University, Zhangjiakou, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Osimertinib resistance, particularly EGFR C797S without T790M, lacks established treatment strategies. We report a 71-year-old woman with stage IVB lung adenocarcinoma harboring EGFR L858R (T790M-negative) who received first-line osimertinib for 29 months until progression. Post-progression ctDNA revealed L858R/C797S (T790M-negative) who received first-line osimertinib for 29 months until progression. Post-progression ctDNA revealed L858R/C797S (T790M-negative). She was subsequently treated with icotinib 125 mg tid, achieving stable disease for 6 months. This case suggests that first-generation EGFR-TKI subsequent therapy may provide short-term disease control in this rare molecular context.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate School, Hebei North University, Zhangjiakou, China.
- Department of Oncology, Hebei General Hospital, Shijiazhuang, China.
- Graduate School, Hebei Medical University, Shijiazhuang, China.
Zitieren
APA
Song, S., Yao, D., Liu, J., Nie, W., He, M., Zhang, J., & Zhao, J. (2026). Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1911991
Vancouver
Song S, Yao D, Liu J, Nie W, He M, Zhang J, et al. Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1911991
BibTeX
@article{Song2026,
author = {Song, Shihang and Yao, Di and Liu, Jinlong and Nie, Wenjing and He, Mengjia and Zhang, Jianqiao and Zhao, Jing},
title = {Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1911991}
}
EUVIMED